Graham, C. N., Maglinte, G. A., Schwartzberg, L. S., Price, T. J., Knox, H. N., Hechmati, G., . . . Fakih, M. G. (2016). Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical therapeutics, 38(6), 1376-1391. https://doi.org/10.1016/j.clinthera.2016.03.023
Citace podle Chicago (17th ed.)Graham, Christopher N., Gregory A. Maglinte, Lee S. Schwartzberg, Timothy J. Price, Hediyyih N. Knox, Guy Hechmati, Jonas Hjelmgren, Beth Barber, a Marwan G. Fakih. "Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy." Clinical Therapeutics 38, no. 6 (2016): 1376-1391. https://doi.org/10.1016/j.clinthera.2016.03.023.
Citace podle MLA (9th ed.)Graham, Christopher N., et al. "Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy." Clinical Therapeutics, vol. 38, no. 6, 2016, pp. 1376-1391, https://doi.org/10.1016/j.clinthera.2016.03.023.